Skip to main content
SpringerLink
Log in

Diagnosis and Management of Gestational Trophoblastic Disease

  • Living reference work entry
  • Latest version View entry history
  • First Online:
Handbook of Gynecology

  • 169 Accesses

Abstract

Gestational trophoblastic disease (GTD) refers to all tumors that arise from the maternal placenta. Gestational trophoblastic neoplasm (GTN) is a subset of GTD and refers to choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Persistent GTD may develop after treatment of a molar pregnancy and is also referred to as GTN. The treatment of GTN is stratified based on whether the patient is low risk or high risk as determined by the World Health Organization (WHO) score and International Federation of Gynecology and Obstetrics (FIGO) staging system. Low-risk GTN is treated with single-agent chemotherapy, whereas high-risk GTN should be treated with combination regimens. GTN that does not respond to first-line treatment is said to be resistant or refractory. Resistance to a particular chemotherapeutic regimen is evidenced by a plateau or rise in beta-hCG levels. The overall prognosis for GTN is excellent, even in the setting of refractory disease. GTN affects women of reproductive age, and comprehensive counseling must be performed prior to initiation of gonadotoxic treatment. This chapter also discusses the management of GTN with special considerations such as brain and vaginal metastasis, role of secondary curettage, and post-molar prophylactic chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abrão RA, de Andrade JM, Tiezzi DG, Marana HR, Candido dos Reis FJ, Clagnan WS. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens. Gynecol Oncol. 2008;108:149–53.

    Article  PubMed  Google Scholar 

  • Alazzam M, Tidy J, Hancock BW, Osborne R, Lawrie TA. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012a: p. CD007102.

    Google Scholar 

  • Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012b;12:CD008891.

    PubMed  Google Scholar 

  • Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, Savage PM, Seckl MJ. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013;31:280–6.

    Article  CAS  PubMed  Google Scholar 

  • Allison KH, Love JE, Garcia RL. Epithelioid trophoblastic tumor: review of a rare neoplasm of the chorionic-type intermediate trophoblast. Arch Pathol Lab Med. 2006;130:1875–7.

    PubMed  Google Scholar 

  • Ayhan A, Ergeneli MH, Yüce K, Yapar EG, Kisnisci AH. Effects of prophylactic chemotherapy for postmolar trophoblastic disease in patients with complete hydatidiform mole. Int J Gynaecol Obstet. 1990;32:39–41.

    Article  CAS  PubMed  Google Scholar 

  • Bagshawe KD, Harland S. Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system. Cancer. 1976;38:112–8.

    Article  CAS  PubMed  Google Scholar 

  • Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112:654–62.

    Article  CAS  PubMed  Google Scholar 

  • Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, Begent RH, Bagshawe KD. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol. 1997;15:2636–43.

    Article  CAS  PubMed  Google Scholar 

  • Cole LA. Hyperglycosylated hCG, a review. Placenta. 2010;31:653–64.

    Article  CAS  PubMed  Google Scholar 

  • Cole LA, Butler SA, Khanlian SA, Giddings A, Muller CY, Seckl MJ, Kohorn EI. Gestational trophoblastic diseases: 2 hyperglycosylated hCG as a reliable marker of active neoplasia. Gynecol Oncol. 2006;102:151–9.

    Article  CAS  PubMed  Google Scholar 

  • Cole LA, Khanlian SA, Muller CY. Detection of perimenopause or postmenopause human chorionic gonadotropin: an unnecessary source of alarm. Am J Obstet Gynecol. 2008;198:275.e1–7.

    Article  PubMed  Google Scholar 

  • Committee, F. O. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet. 2002;77:285–7.

    Article  Google Scholar 

  • Curry SL, Blessing JA, DiSaia PJ, Soper JT, Twiggs LB. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in “poor prognosis” metastatic gestational trophoblastic disease: a gynecologic oncology group study. Obstet Gynecol. 1989;73:357–62.

    CAS  PubMed  Google Scholar 

  • Eiriksson L, Wells T, Steed H, Schepansky A, Capstick V, Hoskins P, Pike J, Swenerton K. Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;124:553–7.

    Article  CAS  PubMed  Google Scholar 

  • Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol. 2003;91:552–7.

    Article  CAS  PubMed  Google Scholar 

  • Evans AC, Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez GC, Hammond CB. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol. 1995;59:226–30.

    Article  PubMed  Google Scholar 

  • Fisher RA, Savage PM, MacDermott C, Hook J, Sebire NJ, Lindsay I, Seckl MJ. The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies. Gynecol Oncol. 2007;107:413–9.

    Article  CAS  PubMed  Google Scholar 

  • Froeling FE, Seckl MJ. Gestational trophoblastic tumours: an update for 2014. Curr Oncol Rep. 2014;16:408.

    Article  PubMed  Google Scholar 

  • Goto S, Ino K, Mitsui T, Kikkawa F, Suzuki T, Nomura S, Mizutani S. Survival rates of patients with choriocarcinoma treated with chemotherapy without hysterectomy: effects of anticancer agents on subsequent births. Gynecol Oncol. 2004;93:529–35.

    Article  CAS  PubMed  Google Scholar 

  • Hammond CB, Weed JC, Currie JL. The role of operation in the current therapy of gestational trophoblastic disease. Am J Obstet Gynecol. 1980;136:844–58.

    Article  CAS  PubMed  Google Scholar 

  • Kohorn EI. Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance? Gynecol Oncol. 2002;85:36–9.

    Article  CAS  PubMed  Google Scholar 

  • Lurain JR. Gestational trophoblastic tumors. Semin Surg Oncol. 1990;6:347–53.

    Article  CAS  PubMed  Google Scholar 

  • Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203:531–9.

    Article  PubMed  Google Scholar 

  • Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204:11–8.

    Article  PubMed  Google Scholar 

  • Lurain JR, Casanova LA, Miller DS, Rademaker AW. Prognostic factors in gestational trophoblastic tumors: a proposed new scoring system based on multivariate analysis. Am J Obstet Gynecol. 1991;164:611–6.

    Article  CAS  PubMed  Google Scholar 

  • Lurain JR, Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol. 1995;172:574–9.

    Article  CAS  PubMed  Google Scholar 

  • Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2005;97:618–23.

    Article  CAS  PubMed  Google Scholar 

  • Lybol C, Sweep FC, Harvey R, Mitchell H, Short D, Thomas CM, Ottevanger PB, Savage PM, Massuger LF, Seckl MJ. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;125:576–9.

    Article  CAS  PubMed  Google Scholar 

  • Matsui H, Suzuka K, Iitsuka Y, Seki K, Sekiya S. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol. 2000;78:28–31.

    Article  CAS  PubMed  Google Scholar 

  • Matsui H, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K, Sekiya S. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol Oncol. 2005;96:616–20.

    Article  CAS  PubMed  Google Scholar 

  • Morrow CP, Kletzky OA, Disaia PJ, Townsend DE, Mishell DR, Nakamura RM. Clinical and laboratory correlates of molar pregnancy and trophoblastic disease. Am J Obstet Gynecol. 1977;128:424–30.

    Article  CAS  PubMed  Google Scholar 

  • Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol. 1991;98:550–7.

    Article  CAS  PubMed  Google Scholar 

  • Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L, Dent J. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984). Br J Obstet Gynaecol. 1986;93:63–9.

    Article  CAS  PubMed  Google Scholar 

  • Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol. 2000;18:854–9.

    Article  CAS  PubMed  Google Scholar 

  • Oncology, F. C. o. G. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105:3–4.

    Article  Google Scholar 

  • Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011;29:825–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, Miller DS. Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. Obstet Gynecol. 2016;128:535–42.

    Article  PubMed  Google Scholar 

  • Papadopoulos AJ, Foskett M, Seckl MJ, McNeish I, Paradinas FJ, Rees H, Newlands ES. Twenty-five years’ clinical experience with placental site trophoblastic tumors. J Reprod Med. 2002;47:460–4.

    PubMed  Google Scholar 

  • Pezeshki M, Hancock BW, Silcocks P, Everard JE, Coleman J, Gillespie AM, Tidy J, Coleman RE. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol. 2004;95:423–9.

    Article  CAS  PubMed  Google Scholar 

  • Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet. 2000;355:712–5.

    Article  CAS  PubMed  Google Scholar 

  • Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, Foskett M, Fuller S, Short D. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996;14:2769–73.

    Article  CAS  PubMed  Google Scholar 

  • Schechter NR, Mychalczak B, Jones W, Spriggs D. Prognosis of patients treated with whole-brain radiation therapy for metastatic gestational trophoblastic disease. Gynecol Oncol. 1998;68:183–92.

    Article  CAS  PubMed  Google Scholar 

  • Schink JC, Singh DK, Rademaker AW, Miller DS, Lurain JR. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol. 1992;80:817–20.

    CAS  PubMed  Google Scholar 

  • Schlaerth JB, Morrow CP, Kletzky OA, Nalick RH, D’Ablaing GA. Prognostic characteristics of serum human chorionic gonadotropin titer regression following molar pregnancy. Obstet Gynecol. 1981;58:478–82.

    CAS  PubMed  Google Scholar 

  • Small W, Lurain JR, Shetty RM, Huang CF, Applegate GL, Brand WN. Gestational trophoblastic disease metastatic to the brain. Radiology. 1996;200:277–80.

    Article  PubMed  Google Scholar 

  • Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB. 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol. 1994;54:76–9.

    Article  CAS  PubMed  Google Scholar 

  • Soper JT, Spillman M, Sampson JH, Kirkpatrick JP, Wolf JK, Clarke-Pearson DL. High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. Gynecol Oncol. 2007;104:691–4.

    Article  CAS  PubMed  Google Scholar 

  • Suzuka K, Matsui H, Iitsuka Y, Yamazawa K, Seki K, Sekiya S. Adjuvant hysterectomy in low-risk gestational trophoblastic disease. Obstet Gynecol. 2001;97:431–4.

    CAS  PubMed  Google Scholar 

  • Uberti EM, Diestel MC, Guimarães FE, De Nápoli G, Schmid H. Single-dose actinomycin D: efficacy in the prophylaxis of post-molar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole. Gynecol Oncol. 2006;102:325–32.

    Article  CAS  PubMed  Google Scholar 

  • Uberti EM, Fajardo MC, da Cunha AG, Rosa MW, Ayub AC, Graudenz MS, Schmid H. Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment. Gynecol Oncol. 2009;114:299–305.

    Article  CAS  PubMed  Google Scholar 

  • van Trommel NE, Massuger LF, Verheijen RH, Sweep FC, Thomas CM. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol. 2005;99:6–13.

    Article  PubMed  Google Scholar 

  • Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Seckl MJ. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol. 2008;19:1578–83.

    Article  CAS  PubMed  Google Scholar 

  • Wang S, An R, Han X, Zhu K, Xue Y. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences. Gynecol Oncol. 2006;103:1105–8.

    Article  CAS  PubMed  Google Scholar 

  • Woolas RP, Bower M, Newlands ES, Seckl M, Short D, Holden L. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynaecol. 1998;105:1032–5.

    Article  CAS  PubMed  Google Scholar 

  • Yarandi F, Jafari F, Shojaei H, Izadi-Mood N. Clinical response to a second uterine curettage in patients with low-risk gestational trophoblastic disease: a pilot study. J Reprod Med. 2014;59:566–70.

    PubMed  Google Scholar 

  • Yingna S, Yang X, Xiuyu Y, Hongzhao S. Clinical characteristics and treatment of gestational trophoblastic tumor with vaginal metastasis. Gynecol Oncol. 2002;84:416–9.

    Article  PubMed  Google Scholar 

  • Yordan EL, Schlaerth J, Gaddis O, Morrow CP. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol. 1987;69:627–30.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA

    Jocelyn Garcia-Sayre, Lynda D. Roman & Koji Matsuo

  2. Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA

    Antonio V. Castaneda

Authors
  1. Jocelyn Garcia-Sayre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio V. Castaneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lynda D. Roman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koji Matsuo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Matsuo .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology and Family Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA

    Donna Shoupe

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG (outside the USA)

About this entry

Cite this entry

Garcia-Sayre, J., Castaneda, A.V., Roman, L.D., Matsuo, K. (2017). Diagnosis and Management of Gestational Trophoblastic Disease. In: Shoupe, D. (eds) Handbook of Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-319-17002-2_11-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17002-2_11-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17002-2

  • Online ISBN: 978-3-319-17002-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Diagnosis and Management of Gestational Trophoblastic Disease
    Published:
    28 March 2017

    DOI: https://doi.org/10.1007/978-3-319-17002-2_11-2

  2. Original

    Diagnosis and Management of Gestational Trophoblastic Disease
    Published:
    05 December 2016

    DOI: https://doi.org/10.1007/978-3-319-17002-2_11-1

Search

Navigation